SCHEMBL4674400

SCHEMBL4674400

O=C(C=C(O)c1nn[nH]n1)c1ccc(Cc2ccccc2F)o1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 1/20 0.36
NCEH1 Q6PIU2 1/20 0.36
ALDH1A1 P00352 5/20 0.36
KMT2A Q03164 4/20 0.36
MEN1 O00255 3/20 0.36
MMEL1 Q495T6 2/20 0.36
TAAR1 Q96RJ0 1/20 0.35
MME P08473 1/20 0.34
TP53 P04637 1/20 0.33
BRS3 P32247 1/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
PTGDR2 Q9Y5Y4 1/20 0.33
LMNA P02545 1/20 0.33
ERCC5 P28715 1/20 0.33
FEN1 P39748 1/20 0.33
KDM4E B2RXH2 1/20 0.33
MAPT P10636 1/20 0.33
HPGD P15428 1/20 0.33
TSHR P16473 1/20 0.33
MAPK1 P28482 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4671110 0.87 CES1 (0.43) CES1NCEH1ALDH1A1MMEL1MME
SCHEMBL4671648 0.85 CES1 (0.34) CES1NCEH1MMEL1MMETP53
SCHEMBL4677051 0.83 TAAR1 (0.37) ALDH1A1KMT2AMEN1TAAR1TP53
SCHEMBL4670701 0.82 CES1 (0.35) CES1NCEH1ALDH1A1KMT2AMEN1
SCHEMBL4674742 0.82 HCAR2 (0.40) CES1NCEH1ALDH1A1MMEL1TP53
SCHEMBL4673698 0.82 PTGDR2 (0.36) CES1NCEH1KMT2AMEN1MMEL1
SCHEMBL4678671 0.81 ALDH1A1 (0.38) CES1NCEH1ALDH1A1MMEL1SMN1; SMN2
SCHEMBL4673269 0.81 ALDH1A1 (0.40) CES1NCEH1ALDH1A1MMEL1TP53
SCHEMBL4677016 0.81 CES1 (0.34) CES1NCEH1MMEL1MMELMNA
SCHEMBL4674475 0.81 CES1 (0.34) CES1NCEH1ALDH1A1MMEL1MME

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 CES1 445/4885NCEH1 1046/4885ALDH1A1 980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.